RMC-6291

· Revolution Medicines, Inc.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for RMC-6291, covering 2026-04-08 to 2026-04-08. Get the full timeline:

Most recent: Clinical Trial Update: Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid Tumors [Phase 1]

See pricing